ReviewAnais brasileiros de dermatologia
Electrocardiogram abnormalities in patients with acne undergoing isotretinoin therapy: a focused review.
Review in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isotretinoin is an extremely successful treatment for acne, widely prescribed for moderate to severe cases unresponsive to conventional therapy that is commonly used in dermatology. While its systemic side effects, particularly those related to hepatic and lipid metabolism, are extensively documented, its impact on cardiac electrophysiology is little understood. Metabolic abnormalities are frequent, with hypertriglyceridemia occurring in up to 44% of patients, elevated total cholesterol in 30%, and transient liver enzyme elevation in approximately 10%-11%. This focused review summarizes the existing research on electrocardiographic (ECG) alterations associated with isotretinoin medication. Reported cardiac abnormalities are rare, with isolated case reports and small studies describing transient arrhythmias in fewer than 1%-2% of users, including premature ventricular contractions (PVCs), atrial tachycardia, and, in exceptionally rare instances, cardiomyopathy < 0.01%. Mechanistic ideas suggest changes in human ether-a-go-go-related gene (hERG) potassium channels, dyslipidemia-induced atherosclerosis, electrolyte imbalances, and sympathetic overactivity. However, large population-based studies have not found a significant increase in major cardiovascular events. Most ECG abnormalities, when noted, appear to be reversible with discontinuing isotretinoin. This review is unique in that it focuses on isotretinoin from both dermatological and cardiac viewpoints. It identifies important shortcomings in standardized ECG monitoring procedures and underscores the scarcity of large, prospective, controlled trials. Future research should focus on longitudinal, multicenter trials using serial ECG evaluations to better define risk profiles and guide clinical monitoring. Understanding infrequent but potentially serious cardiac effects is critical for improving isotretinoin's safety profile and guiding evidence-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.